Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) EBITDA Margin (2018 - 2025)

Serina Therapeutics (SER) has disclosed EBITDA Margin for 8 consecutive years, with 4280.77% as the latest value for Q2 2025.

  • Quarterly EBITDA Margin rose 329962.0% to 4280.77% in Q2 2025 from the year-ago period, while the trailing twelve-month figure was 17099.23% through Dec 2025, up 138827.0% year-over-year, with the annual reading at 18478.46% for FY2025, 1196440.0% up from the prior year.
  • EBITDA Margin hit 4280.77% in Q2 2025 for Serina Therapeutics, down from 39635.71% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 39635.71% in Q4 2024 to a low of 46420.0% in Q1 2024.
  • Historically, EBITDA Margin has averaged 8709.46% across 5 years, with a median of 6914.81% in 2021.
  • Biggest YoY gain for EBITDA Margin was 3962791bps in 2024; the steepest drop was -4321333bps in 2024.
  • Year by year, EBITDA Margin stood at 6914.81% in 2021, then tumbled by -222bps to 22275.0% in 2022, then skyrocketed by 100bps to 7.81% in 2023, then skyrocketed by 507599bps to 39635.71% in 2024, then crashed by -111bps to 4280.77% in 2025.
  • Business Quant data shows EBITDA Margin for SER at 4280.77% in Q2 2025, 39635.71% in Q4 2024, and 9878.57% in Q3 2024.